title: [HIV entry into the cells--mechanisms and therapeutic possibilities].
abstract: Human immunodeficiency virus (HIV) entry into cells is the first step in the viral replication cycle, which has been explored as a new therapeutic target. A better knowledge of the mechanisms involved in the entry process has led to the development of agents, which may inhibit each of the different steps of the viral entry process: attachment of the gp120 to the CD4 cell receptor; binding of the gp120 to CCR5 or CXCR4 coreceptors; and the fusion of viral and cell membranes. Entry inhibitors are the latest family of antiretroviral compounds, being enfuvirtide, a fusion inhibitor, the first approved. Several other entry inhibitors are currently in clinical development and hopefully soon will be part of the therapeutic armamentarium against HIV.
authors.affiliation: Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Spain.
authors.forename: Verónica
authors.initials: V
authors.lastname: Briz
authors.forename: Eva
authors.initials: E
authors.lastname: Poveda
authors.forename: Vicente
authors.initials: V
authors.lastname: Soriano
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology*; D065100:CCR5 Receptor Antagonists; D015704:CD4 Antigens; D006678:HIV / Q000187:drug effects* / Q000472:pathogenicity*; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors / Q000494:pharmacology*; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D008561:Membrane Fusion / Q000187:drug effects; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors
chemical_list: D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D015704:CD4 Antigens; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D019718:Receptors, CXCR4